Xigris Side Effects
Generic name: drotrecogin alfa
Note: This document contains side effect information about drotrecogin alfa. Some dosage forms listed on this page may not apply to the brand name Xigris.
Applies to drotrecogin alfa: intravenous powder for injection.
General
The most common side effect associated with drotrecogin alfa (the active ingredient contained in Xigris) has been bleeding.[Ref]
Hematologic
Hematologic side effects have most commonly included bleeding (25% vs 18% with placebo). The majority of events were ecchymoses or gastrointestinal tract bleeding. Serious bleeding has been reported in 3.5% of patients (vs 2% with placebo) and included intracranial hemorrhage, life threatening hemorrhage, and any event requiring 3 or more units of packed red blood cells per days for 2 consecutive days.[Ref]
Serious bleeding events have been reported at the following sites: Gastrointestinal, intra-abdominal, intrathoracic, retroperitoneal, intracranial, genitourinary, skin or soft tissues.[Ref]
More about Xigris (drotrecogin alfa)
- Check interactions
- Reviews (1)
- Dosage information
- During pregnancy
- Drug class: miscellaneous coagulation modifiers
Professional resources
Related treatment guides
References
1. "Product Information. Xigris (drotrecogin alfa)." Lilly, Eli and Company (2001):
2. Bernard GR, Vincent JL, Laterre PF, et al. "Efficacy and safety of recombinant human activated protein C for severe sepsis." N Engl J Med 344 (2001): 699-709
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
